Aclaris Therapeutics, Inc. (ACRS)
USD 3.08
(-5.52%)
USD 3.08
(-5.52%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -117.56 Million USD | -68.73% |
| 2022 | -84.35 Million USD | -94.07% |
| 2021 | -65.06 Million USD | 19.38% |
| 2020 | -48.19 Million USD | 31.25% |
| 2019 | -90.83 Million USD | 45.32% |
| 2018 | -80.78 Million USD | -86.98% |
| 2017 | -53.45 Million USD | -49.12% |
| 2016 | -48.56 Million USD | -135.0% |
| 2015 | -20.66 Million USD | -142.54% |
| 2014 | -8.52 Million USD | -62.43% |
| 2013 | -5.24 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -13.38 Million USD | 32.23% |
| 2024 Q2 | -12.35 Million USD | 21.12% |
| 2023 Q4 | -43.16 Million USD | -36.68% |
| 2023 Q3 | -31.57 Million USD | 8.73% |
| 2023 Q2 | -34.59 Million USD | -10.46% |
| 2023 FY | - USD | -68.73% |
| 2023 Q1 | -31.32 Million USD | -110.5% |
| 2022 Q4 | -14.87 Million USD | 8.61% |
| 2022 Q2 | -27.58 Million USD | -30.76% |
| 2022 Q1 | -21.09 Million USD | -14.09% |
| 2022 FY | - USD | -94.07% |
| 2022 Q3 | -16.28 Million USD | 40.99% |
| 2021 FY | - USD | 19.38% |
| 2021 Q3 | -18.3 Million USD | -124.34% |
| 2021 Q4 | -18.49 Million USD | -1.03% |
| 2021 Q1 | 4.63 Million USD | 134.2% |
| 2021 Q2 | -8.15 Million USD | -275.95% |
| 2020 Q2 | -10.77 Million USD | 30.51% |
| 2020 FY | - USD | 31.25% |
| 2020 Q4 | -13.56 Million USD | -29.57% |
| 2020 Q1 | -15.5 Million USD | 10.28% |
| 2020 Q3 | -10.46 Million USD | 2.88% |
| 2019 Q2 | -10.55 Million USD | 69.95% |
| 2019 Q3 | -20.12 Million USD | -90.75% |
| 2019 FY | - USD | 45.32% |
| 2019 Q4 | -17.28 Million USD | 14.14% |
| 2019 Q1 | -35.1 Million USD | 10.06% |
| 2018 Q3 | -33.06 Million USD | -15.36% |
| 2018 FY | - USD | -86.98% |
| 2018 Q4 | -39.03 Million USD | -18.06% |
| 2018 Q2 | -28.66 Million USD | 6.71% |
| 2018 Q1 | -30.72 Million USD | -20.77% |
| 2017 Q2 | -15.24 Million USD | -18.32% |
| 2017 Q3 | -18.64 Million USD | -22.31% |
| 2017 Q4 | -25.44 Million USD | -36.49% |
| 2017 FY | - USD | -49.12% |
| 2017 Q1 | -12.88 Million USD | -10.78% |
| 2016 Q4 | -11.62 Million USD | -7.86% |
| 2016 Q3 | -10.78 Million USD | 16.83% |
| 2016 FY | - USD | -135.0% |
| 2016 Q1 | -13.11 Million USD | -173.18% |
| 2016 Q2 | -12.96 Million USD | 1.19% |
| 2015 Q3 | -10.64 Million USD | -313.36% |
| 2015 Q1 | -2.62 Million USD | -1.04% |
| 2015 Q4 | -4.8 Million USD | 54.87% |
| 2015 Q2 | -2.57 Million USD | 1.98% |
| 2015 FY | - USD | -142.54% |
| 2014 FY | - USD | -62.43% |
| 2014 Q3 | -2.65 Million USD | -62.98% |
| 2014 Q4 | -2.59 Million USD | 2.26% |
| 2014 Q2 | -1.63 Million USD | 0.0% |
| 2014 Q1 | -1.63 Million USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Bionano Genomics, Inc. | -213.6 Million USD | 44.961% |
| Prenetics Global Limited | -47.89 Million USD | -145.458% |
| Star Equity Holdings, Inc. | -1.68 Million USD | -6868.88% |
| CareDx, Inc | -89.65 Million USD | -31.128% |
| Exact Sciences Corporation | 41.87 Million USD | 380.746% |
| Exagen Inc. | -19.15 Million USD | -513.82% |
| Inotiv, Inc. | -26.5 Million USD | -343.541% |
| Guardant Health, Inc. | -433.3 Million USD | 72.868% |
| Biodesix, Inc. | -37.1 Million USD | -216.861% |
| BioNexus Gene Lab Corp. | -2.48 Million USD | -4630.679% |
| Precipio, Inc. | -4.31 Million USD | -2622.673% |
| iSpecimen Inc. | -9.1 Million USD | -1191.395% |
| Natera, Inc. | -383.27 Million USD | 69.326% |
| Aspira Women's Health Inc. | -16.49 Million USD | -612.904% |
| Standard BioTools Inc. | -54.45 Million USD | -115.886% |
| 23andMe Holding Co. | -291.87 Million USD | 59.721% |
| Castle Biosciences, Inc. | -45.02 Million USD | -161.116% |
| Personalis, Inc. | -96.8 Million USD | -21.443% |
| Applied DNA Sciences, Inc. | -9.59 Million USD | -1125.779% |
| OpGen, Inc. | -29.51 Million USD | -298.377% |
| T2 Biosystems, Inc. | -43.87 Million USD | -167.954% |
| Myriad Genetics, Inc. | -67.8 Million USD | -73.4% |
| ICON Public Limited Company | 1.63 Billion USD | 107.205% |
| NeoGenomics, Inc. | -17.6 Million USD | -567.717% |
| Star Equity Holdings, Inc. | -1.68 Million USD | -6868.88% |
| IDEXX Laboratories, Inc. | 1.21 Billion USD | 109.655% |
| RadNet, Inc. | 292.78 Million USD | 140.154% |
| MDxHealth SA | -30.46 Million USD | -285.864% |
| Psychemedics Corporation | -251 Thousand USD | -46738.645% |
| Illumina, Inc. | -608 Million USD | 80.664% |
| Check-Cap Ltd. | -17.64 Million USD | -566.128% |
| Twist Bioscience Corporation | -176.7 Million USD | 33.468% |
| DarioHealth Corp. | -53.49 Million USD | -119.772% |
| Fulgent Genetics, Inc. | -46.55 Million USD | -152.546% |
| Sera Prognostics, Inc. | -35.28 Million USD | -233.168% |
| ENDRA Life Sciences Inc. | -9.78 Million USD | -1101.506% |
| OPKO Health, Inc. | -65.51 Million USD | -79.445% |
| Medpace Holdings, Inc. | 363.15 Million USD | 132.373% |
| Neogen Corporation | 182.59 Million USD | 164.385% |
| Intelligent Bio Solutions Inc. | -8.81 Million USD | -1234.342% |
| Prenetics Global Limited | -47.89 Million USD | -145.458% |
| Mainz Biomed B.V. | -25.01 Million USD | -370.049% |
| bioAffinity Technologies, Inc. | -7.62 Million USD | -1440.966% |
| Trinity Biotech plc | -24.09 Million USD | -387.862% |
| Neuronetics, Inc. | -22.75 Million USD | -416.565% |
| Sotera Health Company | 514.14 Million USD | 122.866% |
| bioAffinity Technologies, Inc. | -7.62 Million USD | -1440.966% |